Clinical Trials Browser

Resectable Non-Small Cell Lung Cancer

Colorectal Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Lymphoma, Multiple Myeloma

Carcinoma, Hepatocellular, Liver Neoplasms

Uterine Cervical Neoplasms, Lymphatic Metastasis

Resectable Hepatocellular Carcinoma

Carcinoma, Non-Small-Cell Lung

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Nasopharyngeal Carcinoma

Glioblastoma, Oligodendroglioma, Gliosarcoma

Stomach Neoplasms

Basal Cell Nevus Syndrome

Neoplasms, Germ Cell and Embryonal

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Multiple Myeloma

Carcinoma, Renal Cell

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Neoplasm Metastasis, Sarcoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Neo-Kan

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

CERAD-IMMUNE

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

CheckMate 9TN

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

IMMUNOX

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

SBRT as a Vaccination for Metastatic Melanoma

CheckMate 7UA

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma